EFFECT OF BROMOCRIPTINE ON THE PREMENSTRUAL SYNDROME. A DOUBLE‐BLIND CLINICAL TRIAL
EFFECT OF BROMOCRIPTINE ON THE PREMENSTRUAL SYNDROME. A DOUBLE‐BLIND CLINICAL TRIAL
复制标题
溴隐亭对经前综合症的影响。双盲临床试验。
DOI：
10.1111/j.1471-0528.1977.tb12601.x
复制
发表时间：
1977
期刊：
影响因子：
--
通讯作者：
J. Nielsen
中科院分区：
文献类型：
--
作者：
A. Andersen;J. Larsen;O. R. Steenstrup;Birgit Svendstrup;J. Nielsen
21名患有经前综合征的患者在三个月经周期中进行了研究。在一个对照周期后，在周期的黄体期以随机双盲交叉方式给予溴隐亭和安慰剂，每个患者作为自己的对照。溴隐亭剂量2.5 mg，每日2次。血清催乳素水平在卵泡期和黄体期是相同的，除非用溴隐亭降低。血清孕酮和雌二醇-17-β均在正常范围内，治疗过程中无明显变化。药物显著改善了所有经前症状，但乳痛症是唯一一种溴隐亭明显优于安慰剂的症状。
Twenty‐one patients suffering from the premenstrual syndrome were each studied during three menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random double‐blind cross‐over manner, each patient serving as her own control. The dosage of bromocriptine was 2·5 mg twice daily. Serum prolactin levels were found to be equal during the follicular and luteal phases, except when reduced by bromocriptine. Serum progesterone and oestradiol‐17‐β were within normal ranges, and did not change during treatment. Medication considerably improved all the premenstrual symptoms, but mastodynia was the only one where bromocriptine was significantly better than the placebo.